Meeting
2022 ASCO Annual Meeting
Serena-1: Updated analyses from a phase 1 study (parts C/D) of the next-generation oral SERD camizestrant (AZD9833) in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer.
Authors
Mafalda Oliveira
Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
Mafalda Oliveira , Erika P. Hamilton , Jason Incorvati , Begoña Bermejo de la Heras , Emiliano Calvo , Javier García-Corbacho Sr., Manuel Ruiz-Borrego , Christos Vaklavas , Nicholas C. Turner , Eva M. Ciruelos , Manish R. Patel , Anne C. Armstrong , Peter Kabos , Chris Twelves , Tim Brier , Itziar Irurzun-Arana , Teresa Klinowska , Justin P.O. Lindemann , Christopher J. Morrow , Richard D. Baird
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Clinical Trial Registration Number
NCT03616587
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 1032)
DOI
10.1200/JCO.2022.40.16_suppl.1032
Abstract #
1032
Poster Bd #
410
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
SERENA-4: A phase 3 comparison of AZD9833 (camizestrant) plus palbociclib, versus anastrozole plus palbociclib, for patients with ER-positive, HER2-negative advanced breast cancer who have not previously received systemic treatment for advanced disease.
First Author: Seock-Ah Im
Poster
2020 ASCO Virtual Scientific Program
A phase I dose escalation and expansion study of the next generation oral SERD AZD9833 in women with ER-positive, HER2-negative advanced breast cancer.
First Author: Erika Paige Hamilton
Poster
2015 ASCO Annual Meeting
Long-term safety profile of palbociclib (P) in combination with letrozole (L) as first-line treatment for postmenopausal patients with ER+ and HER2- advanced breast cancer (ABC) (PALOMA-1/TRIO-18).
First Author: Dennis J. Slamon
Poster
2015 ASCO Annual Meeting
Clinical efficacy and safety profile of palbociclib (P) in combination with letrozole (L) as first-line treatment in patients (pts) with ER+ and HER2- advanced breast cancer (ABC) who have not received any systemic treatment (ST): A subgroup analysis of PALOMA-1/TRIO-18.
First Author: Richard S. Finn